[HTML][HTML] Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer
Background: The purpose of the study was to evaluate the effects of erlotinib on epidermal
growth factor receptor (EGFR)-related signaling elements in tumor and skin from patients …
growth factor receptor (EGFR)-related signaling elements in tumor and skin from patients …
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and …
M Agulnik, G da Cunha Santos, D Hedley… - Journal of Clinical …, 2007 - ascopubs.org
Purpose Pharmacodynamic tissue studies were conducted on a phase I/II trial of erlotinib
and cisplatin in patients with recurrent or metastatic head and neck squamous cell …
and cisplatin in patients with recurrent or metastatic head and neck squamous cell …
Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma
Background The purpose of this study was to determine if there are differences in biomarker
modulation and epidermal growth factor receptor (EGFR) degradation between the tumor …
modulation and epidermal growth factor receptor (EGFR) degradation between the tumor …
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)
EH Kraut, C Rhoades, Y Zhang, H Cheng… - Cancer chemotherapy …, 2011 - Springer
Purpose This phase I study determined the maximal-tolerated dose, dose-limiting toxicities,
pharmacokinetics, and recommended dose of erlotinib with docetaxel. Patients and methods …
pharmacokinetics, and recommended dose of erlotinib with docetaxel. Patients and methods …
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva)
M Hidalgo, D Bloedow - Seminars in oncology, 2003 - Elsevier
Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of …
D Soulieres, NN Senzer, EE Vokes… - Journal of clinical …, 2004 - ascopubs.org
Purpose To determine the efficacy and safety profiles of erlotinib in patients with advanced
recurrent and/or metastatic squamous cell cancer of the head and neck (HNSCC). Patients …
recurrent and/or metastatic squamous cell cancer of the head and neck (HNSCC). Patients …
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma
F Thomas, P Rochaix, M White-Koning… - European Journal of …, 2009 - Elsevier
A clinical study was conducted to determine the safety and efficacy of neoadjuvant erlotinib
treatment in patients with head and neck squamous cell carcinoma [Thomas F, Rochaix P …
treatment in patients with head and neck squamous cell carcinoma [Thomas F, Rochaix P …
Erlotinib and gefitinib responsiveness in head and neck cancer cell lines—a comparing analysis with cetuximab
S Hartmann, N Neckel, A Seher, G Mutzbauer… - Clinical oral …, 2016 - Springer
Objective The objective of this study is to examine the efficacy of erlotinib and gefitinib with
respect to epidermal growth factor (EGF) and cetuximab response in head and neck cancer …
respect to epidermal growth factor (EGF) and cetuximab response in head and neck cancer …
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor …
AR Tan, X Yang, SM Hewitt, A Berman… - Journal of Clinical …, 2004 - ascopubs.org
Purpose To evaluate changes in epidermal growth factor receptor (EGFR) phosphorylation
and its downstream signaling in tumor and surrogate tissue biopsies in patients with …
and its downstream signaling in tumor and surrogate tissue biopsies in patients with …
[HTML][HTML] Dosing to rash?–The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash
M Steffens, T Paul, V Hichert, C Scholl… - European Journal of …, 2016 - Elsevier
Aim The aim of this study was to investigate if biomarkers of individual drug metabolism,
respectively, the erlotinib/O-desmethyl-erlotinib metabolic ratio, may be a predictive factor for …
respectively, the erlotinib/O-desmethyl-erlotinib metabolic ratio, may be a predictive factor for …
相关搜索
- head and neck cell carcinoma
- neck cancer skin of patients
- head and neck samples of patients
- head and neck skin tissue
- neck cancer operable head
- treatment with erlotinib pharmacokinetics in patients
- samples of patients skin tissue
- patient serum skin rash
- pharmacokinetics and pharmacodynamics erlotinib tarceva
- head and neck combination with docetaxel
- treatment with erlotinib breast cancer
- breast cancer pharmacokinetics in patients
- neck cancer patients with head
- head and neck cell cancer